|Watson Pharmaceuticals Receives FDA Approval for Citalopram Hydrobromide Tablets 10MG, 20MG and 40MG|
CORONA, Calif., Nov 8, 2004 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for citalopram hydrobromide tablets, in the 10 mg, 20 mg and 40 mg strengths.
Citalopram hydrobromide tablets are the generic version of Forest Laboratories' Celexa(R), which is indicated for the treatment of depression. The Company expects to initiate shipments of the product in the near future. For the 12-months ending June 2004, Celexa(R) had sales of approximately $1.4 billion, according to IMS Health data.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com.
Forward-Looking Statement Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing, market acceptance of and continued demand for Watson's products, difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2003 and Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2004.
Celexa(R) is a registered trademark of Forest Laboratories, Inc.
SOURCE Watson Pharmaceuticals, Inc.
Patty Eisenhaur (Investors), 951-493-5611